Search

Displaying results 1721 - 1730 of 10000 in total
  1. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma

  2. Drug

    Celivarone

    go.drugbank.com/drugs/DB16012
    Investigational

    Celivarone is under investigation in clinical trial NCT00233441 (Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as … Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/flutter).

  3. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113] … [A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products.

  4. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    [L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.

    Products: XOFLUZA 20 MG FİLM KAPLI TABLET, 2 ADET, XOFLUZA 20 MG FİLM KAPLI TABLET, 4 ADET
  5. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy. … [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric

  6. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

  7. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

  8. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes … As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis.

    Mixtures: TOBRALOT 5 MG+3 MG/ML GÖZ DAMLASI, SÜSPANSİYON, 1 ADETProducts: LOTEMAX 5MG/ML GÖZ DAMLASI, SÜSPANSİYON, 5 ML
  9. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume … Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.

  10. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow … It is currently marketed under the trademark TEMODAR® by Merck.[L32033]

    Products: TEMODAL 5MG HARTKAP IN BTL, TEMODAL 140MG HKP IN BTL